Malignant Neoplasms of the Rectum
Philip H. Gordon, Santhat Nivatvongs, Lee E. Smith, Scott Thorn Barrows, Carla Gunn, Gregory Blew, David Ehlert, Craig Kiefer, Kim Martens in Neoplasms of the Colon, Rectum, and Anus, 2007
Kim et al. (365) assessed the safety of TME with pelvic autonomic nerve preservation in terms of voiding and sexual function in males with rectal carcinoma. They performed urine flowmetry using Urodyn and a standard questionnaire using the International Index of Erectile Function and the International Prostate Symptom Score before and after surgery in 68 males with rectal carcinoma. Significant differences in mean maximal urinary flow rate and voided volume were seen before and after operation but no differences in residual volume before and after operation were apparent. The total International Prostate Symptom Score was increased after operation. Five International Index of Erectile Function domain scores (erectile function, intercourse satisfaction, orgasmic function, sexual desire, and overall satisfaction) were significantly decreased after operation. Erection was possible in 80.9%; penetration ability was possible in 75%. Complete inability for erection and intercourse was observed in 5.5%. Retrograde ejaculation was noted in 13.2%. International Index of Erectile Function domains such as sexual desire and overall satisfaction were greatly decreased in 57.4% and 63.2%, respectively.
Complementary and Alternative Medicine in Older Adults
K. Rao Poduri in Geriatric Rehabilitation, 2017
In 2007, a randomized multicenter clinical trial of over 900 BPH patients was conducted from September 2002 to December 2003 across seven therapeutic drug groups, including selective adrenoceptor antagonist (terazosin, doxazosin, tamsulosin, naftopidil), 5-alpha-reductase inhibitor (finasteride, epristeride), and natural product (cernilton, prepared from Secale cereale [rye] pollen). According to baseline, at average follow-up of 6 months, no difference in the International Prostate Symptom Score was noted across the therapeutic intervention groups. However, prostatic volume and transitional zone volume were significantly decreased in the 5-alpha-reductase inhibitor group, and more significant symptomatic improvements were noted in the cernilton, doxazosin, and naftopidil groups.190
Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS)
Manit Arya, Taimur T. Shah, Jas S. Kalsi, Herman S. Fernando, Iqbal S. Shergill, Asif Muneer, Hashim U. Ahmed in MCQs for the FRCS(Urol) and Postgraduate Urology Examinations, 2020
Which of the following is FALSE regarding the International Prostate Symptom Score?The questionnaire has eight questions.The first seven questions are graded from 1 to 5.Includes a question grading the symptom of intermittent flow.A score of 8 signifies moderate LUTS.A score of 20 signifies severe LUTS.
The voiding VAS score is a simple and useful method for predicting POUR after laparoscopy for benign gynaecologic diseases: a pilot study
Published in Journal of Obstetrics and Gynaecology, 2022
Woo Yeon Hwang, Kidong Kim, Hye Yon Cho, Eun Joo Yang, Dong Hoon Suh, Jae Hong No, Jung Ryeol Lee, Jung Won Hwang, Sang-Hwan Do, Yong Beom Kim
A scoring system that allows surgeons to estimate the possibility of POUR in patients undergoing gynaecologic laparoscopic surgery would be a more easily applicable alternative. The International Prostate Symptom Score (IPSS), a self-administered questionnaire developed and validated by the American Urological Association, is such a scoring system, and is most commonly used to assess lower urinary tract symptoms (Barry et al. 1992; Fujimura et al. 2012; Jiang et al. 2013). The voiding visual analogue scale (VAS) is another tool for the assessment of postoperative voiding. These tools would enable the identification of patients at high risk of POUR and administration of appropriate management. In addition, we investigated the correlation between pain and POUR using the Brief Pain Inventory (BPI) (Yun et al. 2004).
Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial
Published in Current Medical Research and Opinion, 2018
Jae Hoon Chung, Cheol Young Oh, Jae Heon Kim, U-Syn Ha, Tae Hyo Kim, Seung Hwan Lee, Jun Hyun Han, Jae Hyun Bae, In Ho Chang, Deok Hyun Han, Tag Keun Yoo, Jae Il Chung, Sae Woong Kim, Jina Jung, Yong-Il Kim, Seung Wook Lee
A prospectively randomized, double-blinded, phase 3 trial was performed between October 2014 and June 2015 at 13 medical institutions in Korea. LUTS/BPH patients were evaluated using the International Prostate Symptom Score (IPSS) and uroflowmetry. The inclusion criteria were as follows: (1) 45 year old or older males who were diagnosed with BPH; (2) total IPSS of 13 points or higher; (3) peak urine flow rate (Qmax) between 4 and 15 mL/s and voided urine volumes of 100 mL or more; (4) post-void residual (PVR) volume <300 mL; and (5) subjects who were informed of objectives, methods, effects and risks of the trial, and voluntarily signed a written consent form or had their representatives sign it. The following patients were excluded from the study: (1) subjects to whom tamsulosin was contraindicated; (2) serum prostate-specific antigen (PSA) ≥ 4 ng/mL; (3) the presence of other diseases, besides BPH, that were suspected to cause dysuria, or a history of other conditions that could change urination speed (e.g. neurogenic bladder, urethral stricture, acute or chronic prostatitis, urinary tract infection); (4) patients who were diagnosed with a malignant genitourinary tumor; (5) a surgery or procedure that could affect the urination function was performed in the past or was planned; and (6) patients with peripheral or central neurogenic disorders, cardiovascular disease or uncontrolled endocrinopathy.
Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms
Published in The Aging Male, 2022
Liliana Vartolomei, Andrei Cotruș, Sabin Octavian Tătaru, Mihai Dorin Vartolomei, Adrian Man, Matteo Ferro, Camelia Stanciu, Anca Ileana Sin, Shahrokh F. Shariat
International Prostate Symptom Score [12,13] was used to assess LUTS, with a stratification as recommended: 0–7 mildly symptomatic, 8–19 moderately symptomatic, and 20–35 severely symptomatic. IIEF-5 was used to assess ED, with a stratification as recommended: 17–25 mild to no ED, 12–16 mild-to-moderate ED, 8–11 moderate ED, and 5–7 severe ED [14]. DASS-21 [15,16] was used to determine depression, anxiety, and stress symptoms within the studied population. This is a tool that evaluates the severity of behavioral and emotional symptoms that are correlated with depression, anxiety disorder and stress. There are 21 items that were scored: depression symptoms related items: 3, 5, 10, 13, 16, 17, and 21; anxiety disorder related items: 2, 4, 7, 9, 15, 19, and 20; and stress related items: 1, 6, 8, 11, 12, 14, and 18. Each of the questions was rated from 0 to 3. Therefore each of the axes presents partial scores of 0 to 18–24 depending on the number of questions assigned. According to subscale results, patients were assigned to one of four categories (normal, mild, moderate, and severe symptoms): depression symptoms (0–4 normal, 5–6 mild, 7–10 moderate, and severe ≥11); anxiety symptoms (0–3 normal, 4–5 mild, 6–7 moderate, and severe ≥8); and stress symptoms (0–7 normal, 8–9 mild, 10–12 moderate, and severe ≥13). Sub-analysis was performed also according to symptoms vs. no symptoms of depression (cut-off 4), anxiety (cut-off 3), and stress (cut-off 7).
Related Knowledge Centers
- Benign Prostatic Hyperplasia
- Lower Urinary Tract Symptoms
- Nocturia
- Quality of Life
- Screening
- Urination
- Frequent Urination
- Quality of Life
- Vesical Tenesmus
- Mnemonic
- Urodynamic Testing